S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)

Chemours Stock Forecast, Price & News

$29.35
-1.69 (-5.44%)
(As of 11/30/2021 12:15 PM ET)
Add
Compare
Today's Range
$29.34
$30.71
50-Day Range
$27.01
$33.16
52-Week Range
$23.30
$38.87
Volume
17,901 shs
Average Volume
1.22 million shs
Market Capitalization
$4.78 billion
P/E Ratio
12.54
Dividend Yield
3.24%
Beta
2.12
30 days | 90 days | 365 days | Advanced Chart
Receive CC News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemours and its competitors with MarketBeat's FREE daily newsletter.


Chemours logo

About Chemours

The Chemours Co. is a holding company that engages in the provision of performance chemicals. The firm deliver solutions, which include a range of industrial and chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, mining, and oil & gas. It operates through the following segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment engages in manufacturing of titanium dioxide pigment. The Thermal & Specialized Solutions segment is a provider of refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a provider of polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment with its Mining Solutions & Performance Chemicals and Intermediates engages in businesses that produce industrial chemicals used in applications by customers, which

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
N/A
Fax
N/A
Employees
6,500
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.97 billion
Cash Flow
$3.81 per share
Book Value
$4.95 per share

Profitability

Net Income
$219 million
Pretax Margin
6.56%

Debt

Price-To-Earnings

Miscellaneous

Free Float
158,431,000
Market Cap
$4.78 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Ex-Dividend
11/12/2021
Today
11/30/2021
Dividend Payable
12/15/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

MarketRank

Overall MarketRank

3.28 out of 5 stars

Basic Materials Sector

8th out of 220 stocks

Chemicals & Allied Products Industry

3rd out of 20 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 2.5Insider Behavior: 2.5Valuation: 3.8 5 -4 -3 -2 -1 -












Chemours (NYSE:CC) Frequently Asked Questions

Is Chemours a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chemours stock.
View analyst ratings for Chemours
or view top-rated stocks.

How has Chemours' stock price been impacted by COVID-19 (Coronavirus)?

Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CC stock has increased by 176.6% and is now trading at $29.49.
View which stocks have been most impacted by COVID-19
.

When is Chemours' next earnings date?

Chemours is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Chemours
.

How were Chemours' earnings last quarter?

The Chemours Company (NYSE:CC) announced its quarterly earnings data on Thursday, November, 4th. The specialty chemicals company reported $1.27 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.99 by $0.28. The specialty chemicals company had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.58 billion. Chemours had a net margin of 6.51% and a trailing twelve-month return on equity of 72.01%. The company's quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 earnings per share.
View Chemours' earnings history
.

How often does Chemours pay dividends? What is the dividend yield for Chemours?

Chemours declared a quarterly dividend on Wednesday, October 27th. Shareholders of record on Monday, November 15th will be given a dividend of $0.25 per share on Wednesday, December 15th. This represents a $1.00 annualized dividend and a yield of 3.39%. The ex-dividend date is Friday, November 12th.
View Chemours' dividend history
.

Is Chemours a good dividend stock?

Chemours pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.24%. The dividend payout ratio of Chemours is 42.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemours will have a dividend payout ratio of 22.78% next year. This indicates that Chemours will be able to sustain or increase its dividend.
View Chemours' dividend history.

What guidance has Chemours issued on next quarter's earnings?

Chemours issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of $3.930-$4.130 for the period, compared to the Thomson Reuters consensus estimate of $3.670. The company issued revenue guidance of -.

What price target have analysts set for CC?

9 Wall Street analysts have issued twelve-month price objectives for Chemours' shares. Their forecasts range from $28.00 to $48.00. On average, they anticipate Chemours' share price to reach $38.33 in the next year. This suggests a possible upside of 30.0% from the stock's current price.
View analysts' price targets for Chemours
or view top-rated stocks among Wall Street analysts.

Who are Chemours' key executives?

Chemours' management team includes the following people:
  • Mark E. Newman, President, CEO, COO, Director & Senior VP
  • Sameer Ralhan, Chief Financial Officer & Senior Vice President
  • Randal King, VP-Technology & Advanced Performance Materials
  • David C. Shelton, Secretary, Senior Vice President & General Counsel
  • Camela T. Wisel, Chief Accounting Officer, VP & Controller

What is Mark Vergnano's approval rating as Chemours' CEO?

106 employees have rated Chemours CEO Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among Chemours' employees.

What other stocks do shareholders of Chemours own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

What is Chemours' stock symbol?

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Who are Chemours' major shareholders?

Chemours' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.43%), LSV Asset Management (2.27%), Vaughan Nelson Investment Management L.P. (1.34%), Geode Capital Management LLC (1.35%), Bank of New York Mellon Corp (1.34%) and Dimensional Fund Advisors LP (1.27%). Company insiders that own Chemours stock include Alvenia Scarborough, David C Shelton, Denise Dignam, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, Richard H Brown and Sameer Ralhan.
View institutional ownership trends for Chemours
.

Which major investors are selling Chemours stock?

CC stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Invesco Ltd., Two Sigma Advisers LP, Independent Advisor Alliance, Schroder Investment Management Group, LSV Asset Management, Russell Investments Group Ltd., and AXA S.A.. Company insiders that have sold Chemours company stock in the last year include Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, and Sameer Ralhan.
View insider buying and selling activity for Chemours
or view top insider-selling stocks.

Which major investors are buying Chemours stock?

CC stock was acquired by a variety of institutional investors in the last quarter, including Luminus Management LLC, Renaissance Technologies LLC, Millennium Management LLC, Balyasny Asset Management LLC, EMG Holdings L.P., American Century Companies Inc., PEAK6 Investments LLC, and Los Angeles Capital Management LLC. Company insiders that have bought Chemours stock in the last two years include E Bryan Snell, Mark Newman, and Richard H Brown.
View insider buying and selling activity for Chemours
or or view top insider-buying stocks.

How do I buy shares of Chemours?

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemours' stock price today?

One share of CC stock can currently be purchased for approximately $29.49.

How much money does Chemours make?

Chemours has a market capitalization of $4.81 billion and generates $4.97 billion in revenue each year. The specialty chemicals company earns $219 million in net income (profit) each year or $2.34 on an earnings per share basis.

How many employees does Chemours have?

Chemours employs 6,500 workers across the globe.

What is Chemours' official website?

The official website for Chemours is www.chemours.com.

Where are Chemours' headquarters?

Chemours is headquartered at 1007 MARKET STREET, WILMINGTON DE, 19801.

How can I contact Chemours?

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.